Progression and response predictive factors of diabetic macular edema in patients treated with intravitreal therapy
Author: Angel Gutierrez Merino (Spain)
Co-authors: Maria Isabel Lopez Galvez
Purpose
To study the safety and efficacy of PRN (pro re nata) pattern of ranibizumab in patients with naive diabetic macular edema (DME) in clinical practice and to study the relationship between diabetes ́s systemic management, OCT biomarkers and patient´s evolution, in order to establish factors that may predict the response to treatment.
Setting/Venue
This study was performed in the retina section of the Ophthalmology department of the HCUV (Hospital Clínico Universitario de Valladolid).
Methods
Retrospective transversal study from patient records from patients under treatment with ranibizumab and PRN pattern in 2017 and their OCT images. Data were studied using descriptive and inferential analysis systems.
Results
After treatment, all patients were stable or achieved better anatomical and functional outcomes. The mean number of letters gained of best corrected visual acuity (BCVA) was 5,77 ± 6,41 letters. The average number of injections was 4,53 ± 2,06 (under 7 recommended injections on the first year of treatment). There was a CMT decrease of 110,77 ± 93,95 μm. Macular volume had a beneficial evolution too: Basal macular volume was 9,71 ± 1,65mm3 and final macular volume was 8,43 ± 1,17mm3. There was no relationship between systemic factors and DME evolution. No safety issues were found. Higher values of initial CMT and DME volume were related to better anatomical evolution after treatment (p<0,05).
Conlusions
Ranibizumab treatment with PRN pattern is effective for maintenance and improvement of visual function in DME. Patients with higher initial macular volume and higher CMT had better anatomical evolution after treatment. Alternatives for treatment and follow-up should be considered as injections and visits are below recommended values.